General Information of Drug (ID: DM5YHU2)

Drug Name
Avoralstat Drug Info
Synonyms
TUWMKPVJGGWGNL-UHFFFAOYSA-N; UNII-UX17773O15; UX17773O15; 918407-35-9; Avoralstat [INN]; 3-(2-((4-Carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid; 3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]pyridine-2-carboxylic acid; SCHEMBL17513082; AKOS030629101; DB12120; CS-7551; 2-Pyridinecarboxylic acid, 3-(2-(((4-(aminoiminomethyl)phenyl)amino)carbonyl)-4-ethenyl-5-met
Indication
Disease Entry ICD 11 Status REF
Hereditary angioedema 4A00.14 Phase 2/3 [1]
Cross-matching ID
PubChem CID
86566678
CAS Number
CAS 918407-35-9
TTD Drug ID
DM5YHU2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Tissue kallikrein (KLK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VDA-1102 DMAJ85O Actinic keratosis EK90.0 Phase 2 [3]
JNJ-69086420 DM6VR13 Prostate cancer 2C82.0 Phase 1 [4]
JNJ-78278343 DM27FAN Prostate cancer 2C82.0 Phase 1 [5]
JNJ-75229414 DMV6XBC Prostate cancer 2C82.0 Phase 1 [6]
Dermolastin DM6WSU2 Atopic dermatitis EA80 Discontinued in Phase 2 [7]
DM-107 DMRYQVJ Atopic dermatitis EA80 Investigative [8]
hK2p01 derivative KLK2 inhibitor DME13RQ Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Kininogen (KNG1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CU201 (B9870) DMDPJWF Discovery agent N.A. Investigative [10]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Kininogen (KNG1) TTDJ4MY KNG1_HUMAN Inhibitor [2]
Tissue kallikrein (KLK2) TTJLNAW KLK2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02303626) 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Vidac Pharma.
4 ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
6 ClinicalTrials.gov (NCT05022849) A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
7 Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).
9 Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60.
10 Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May;8(5):1280-7.